Distinguished in Dementia

Jacques Hugon

Paris, FR 
Distinguished in Dementia
Paris, FR 
OverviewLocationsClinical Research

Overview

Jacques Hugon practices in Paris, France. Mr. Hugon is rated as a Distinguished expert by MediFind in the treatment of Dementia. His top areas of expertise are Alzheimer's Disease, Dementia, Long Haul COVID, and Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.

His clinical research consists of co-authoring 203 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 84 articles and participated in 3 clinical trials in the study of Dementia.

Gender
Male

Locations

Paris, France
Other Locations
La Seyne-sur-mer, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Drug
Study Drugs: Flutemetamol, Florbetapir
Study Phase: Phase 3
MEMENTO-VAScular COmponents of Dementia
MEMENTO-VAScular COmponents of Dementia
Enrollment Status: Completed
Publish Date: January 28, 2022
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

202 Total Publications

Dual risk of anticholinergic burden and CSF alzheimer's biomarkers in older patients: a mortality follow-up study from daily medical practice.
Dual risk of anticholinergic burden and CSF alzheimer's biomarkers in older patients: a mortality follow-up study from daily medical practice.
Journal: Alzheimer's research & therapy
Published: May 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hugon's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile